赛诺菲安万特（SNY）今日盘前大涨5.05%，引起市场广泛关注。这一涨幅主要源于公司发布的三季度财报显示业绩超出市场预期，特别是其旗舰药物Dupixent的销售表现亮眼。
根据财报，赛诺菲三季度营收达124.3亿欧元，同比增长2.3%。按固定汇率计算，每股收益为2.91欧元，远超分析师平均预估的2.65欧元。这一强劲的业绩表现为公司股价提供了有力支撑。
Dupixent作为赛诺菲的重要增长引擎，三季度销售额同比增长26.2%，达到创纪录的41.6亿欧元，单季度首次突破40亿欧元大关。这款用于治疗特应性皮炎和哮喘等多种疾病的药物，预计年收入峰值将超过210亿欧元。尽管Dupixent将于2031年失去专利保护，但公司正积极寻找新药以应对这一挑战。
值得注意的是，赛诺菲的疫苗业务表现较为疲软，销售额下降7.8%至34亿欧元，主要受到流感疫苗销售额下降的影响。尽管如此，公司仍然重申了全年业绩指引，显示出对未来发展的信心。此外，赛诺菲正在推动多个潜在畅销药物通过临床试验，这些积极因素综合推动了公司股价的强劲上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.